No Data
No Data
Olin Biology (688319.SH): Trivalent influenza virus split lytic vaccine (MDCK cells) has obtained the drug clinical trial approval notification.
On October 21, Olin biotechnology (688319.SH) announced that it has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration regarding the trivalent influenza virus split vaccine (MDCK cells). After receiving the influenza vaccine, it can stimulate the body to produce immunity against influenza viruses, used to prevent epidemic influenza caused by vaccine-related types of influenza viruses. Based on the vaccine components and the types of viruses prevented, the influenza vaccines currently available in China include trivalent influenza vaccines and quadrivalent influenza vaccines, with trivalent influenza vaccines mainly preventing H1N1 and H3N2 in influenza A.
Earnings Preview: Olin to Report Financial Results Post-market on October 24
Earnings Preview: Olin (OLN) Q3 Earnings Expected to Decline
We Like These Underlying Return On Capital Trends At Olin (NYSE:OLN)
RBC Capital Maintains Olin(OLN.US) With Buy Rating, Maintains Target Price $52
Olin (NYSE:OLN) Might Have The Makings Of A Multi-Bagger